Sorrento Therapeutics (SRNE) is Initiated by FBR Capital to Outperform, Price Target at $22

Sorrento Therapeutics (SRNE) is Initiated by FBR Capital to Outperform according to the research report released to the investors. The brokerage firm has set the Price Target of the shares at $22. The shares recommendation by the Brokerage Firm was released on Dec-22-2015.